CALGARY, Oct. 22 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that a poster presentation authored by Prof. Hardev Pandha of The Royal Surrey Hospital, U.K., entitled "Synergistic Anti-Tumour Activity of Oncolytic Reovirus and Cisplatin in a B16.F10 Mouse Melanoma Model" is scheduled to be presented October 23, 2008 at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. The conference is being held in Geneva, Switzerland, from October 21-24, 2008.
In the study, the researchers examined the in vitro and in vivo oncolytic activity of reovirus in combination with cisplatin against a mouse melanoma cell line. The researchers demonstrated that the combined therapy results in significantly increased cell death in vitro compared to either agent alone. In the mouse model, combined therapy suppressed tumour growth and significantly prolonged median survival time. The researchers concluded that the addition of chemotherapeutic agents can significantly enhance the anti-tumour efficacy of reovirus therapy and justify formal clinical evaluation.
This research supports the ongoing U.K. clinical trial examining the combination of REOLYSIN(R) with carboplatin and paclitaxel (REO 011) in patients with advanced cancers. An abstract covering interim results of the trial is expected to be available tomorrow in the Journal of Immunotherapy, the official journal of the International Society for Biological Therapy of Cancer (iSBTc). A poster presentation which will include current results from the trial is scheduled to be presented at the iSBTc conference in San Diego, CA on November 1, 2008.
The poster will be available today on the Oncolytics website at http://www.oncolyticsbiotech.com.
The EORTC-NCI-AACR symposium is held on an annual basis and is jointly
organized by the European Organization for Research and Treatment
|SOURCE Oncolytics Biotech Inc.|
Copyright©2008 PR Newswire.
All rights reserved